Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PTEN inact mut XL147 prostate adenocarcinoma sensitive detail...
PTEN inact mut Paclitaxel + XL147 prostate adenocarcinoma sensitive detail...
Unknown unknown NSC23766 prostate adenocarcinoma not applicable detail...
Unknown unknown ONC201 prostate adenocarcinoma not applicable detail...
ATM L1449* Olaparib prostate adenocarcinoma predicted - sensitive detail...
Unknown unknown VT-464 prostate adenocarcinoma not applicable detail...
BRAF K601E Trametinib prostate adenocarcinoma no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00002651 Phase III Bicalutamide Goserelin Hormone Therapy in Treating Men With Stage IV Prostate Cancer Completed CAN 0
NCT00223665 Phase II Leuprolide Flutamide Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical Prostatectomy Completed USA 0
NCT00536991 Phase Ib/II Prednisone Calcitriol Ketoconazole Calcitriol, Ketoconazole, and Hydrocortisone in Treating Patients With Advanced or Recurrent Prostate Cancer Terminated USA 0
NCT00541047 Phase III Leuprolide Goserelin Bicalutamide Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS) Active, not recruiting CAN 1
NCT00589420 Phase II Docetaxel + Sorafenib Sorafenib and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy Completed USA 0
NCT00720785 Phase I Bortezomib Natural Killer Cells and Bortezomib to Treat Cancer Completed USA 0
NCT00859781 Phase II Prednisone Ketoconazole 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer Recruiting USA 0
NCT00936390 Phase III Flutamide Goserelin Leuprolide Triptorelin Bicalutamide Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer Active, not recruiting USA | CAN 0
NCT01174199 Phase I Temsirolimus + Vorinostat Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer Terminated USA 0
NCT01313559 Phase II Everolimus + Pasireotide Pasireotide Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer Terminated USA 0
NCT01342367 Phase I Bicalutamide Dutasteride Finasteride Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer Active, not recruiting USA 0
NCT01409200 Phase II Axitinib Neoadjuvant Axitinib in Prostate Cancer Active, not recruiting USA 0
NCT01420250 Phase I Bicalutamide Cabazitaxel Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer Active, not recruiting USA 0
NCT01485861 Phase II GDC-0980 Abiraterone Ipatasertib Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy Active, not recruiting USA 8
NCT01498978 Phase II Ipilimumab Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Completed USA 0
NCT01503229 Phase II Prednisone Abiraterone Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Completed USA 0
NCT01513733 Phase I Tasquinimod Cabazitaxel The CATCH Prostate Cancer Trial Cabazitaxel And Tasquinimod in Men With Prostate Cancer Completed USA 0
NCT01548807 Phase I Everolimus Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy Completed USA 0
NCT01560923 Phase II Sipuleucel-T Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer Completed USA 0
NCT01619813 Phase II Docetaxel + Prednisone Pelareorep Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer Completed CAN 0
NCT01630590 Phase II Cabozantinib Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer Completed USA 0
NCT01681433 Phase II Prednisone Abiraterone Apatorsen OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone Terminated USA | CAN 0
NCT01688492 Phase Ib/II Abiraterone + Prednisone Ipilimumab Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer Active, not recruiting USA 0
NCT01695473 Phase II Buparlisib Neoadjuvant BKM120 in High-risk Prostate Cancer Terminated USA 0
NCT01703065 Phase I Cabozantinib Cabozantinib in Treating Men With Castration-Resistant Prostate Cancer Terminated USA 0
NCT01706458 Phase II pTVG-HP plasmid DNA vaccine Sipuleucel-T Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer Completed USA 0
NCT01709734 Phase II Galeterone A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer Completed USA | CAN 0
NCT01786265 Phase II Goserelin Degarelix Abiraterone Prednisone Leuprolide Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone Active, not recruiting USA 0
NCT01787331 Phase II Itraconazole A Phase II Study of Itraconazole in Biochemical Relapse Completed USA 0
NCT01790126 Phase II Apalutamide The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer Completed USA 0
NCT01804465 Phase II Ipilimumab A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer Completed USA 0
NCT01807065 Phase II Sipuleucel-T Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer Completed USA 0
NCT01812668 Phase I Cabozantinib Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer Completed USA 0
NCT01832259 Phase II Pazopanib A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection Completed USA 0
NCT01845792 Phase II Cabazitaxel Abiraterone Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer Terminated USA 0
NCT01848067 Phase Ib/II Abiraterone Prednisone Alisertib Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer Completed USA 0
NCT01885949 Phase II Enzalutamide + Tivozanib Tivozanib + Enzalutamide in Adv Prostate Cancer Active, not recruiting USA 0
NCT01927627 Phase II Enzalutamide Enzalutamide in Patients With High-risk Prostate Cancer Completed USA 0
NCT01940276 Phase II Abiraterone + Prednisone Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer Completed USA 0
NCT01942837 Phase II Enzalutamide Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling Active, not recruiting USA 0
NCT01946204 Phase III Apalutamide A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN) Active, not recruiting USA | CAN 23
NCT01949337 Phase III Abiraterone Prednisone Enzalutamide Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer Active, not recruiting USA | CAN 1
NCT01961843 Phase I Prednisone Abiraterone Abiraterone Acetate for Castrate Resistant Prostate Cancer Active, not recruiting USA 0
NCT01977651 FDA approved Enzalutamide A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide Completed USA | CAN 18
NCT01996696 Phase II Metformin A Study With or Without Metformin to Determine if Metformin Can Prevent Weight Gain and Other Problems (i.e. Diabetes, Increased Cholesterol, Etc.) That Can Arise From the Use of Hormonal Therapy in Combination With Radiation Therapy When Treating Aggressive Localized Prostate Cancer. Recruiting CAN 0
NCT02003924 Phase III Enzalutamide Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer Active, not recruiting USA | CAN 30
NCT02023463 Phase I Goserelin Enzalutamide Leuprolide Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer Active, not recruiting USA 0
NCT02025010 Phase II Abiraterone Phase II Clinical Trial of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer With Correlative Assessment of Hormone Intermediates. Active, not recruiting USA 0
NCT02034552 Phase II Prednisone Radium Ra 223 dichloride Enzalutamide Abiraterone A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC) Completed USA 0
NCT02036918 Phase I Sipuleucel-T Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer Completed USA 0
NCT02043678 Phase III Prednisone Abiraterone Radium Ra 223 dichloride Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms Active, not recruiting USA | CAN 17
NCT02057939 Phase II Enzalutamide Leuprolide Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM) Completed USA 0
NCT02058706 Phase II Goserelin Bicalutamide Enzalutamide Leuprolide LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer Active, not recruiting USA 0
NCT02064036 Phase I Bicalutamide Goserelin Leuprolide Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate Recruiting USA 0
NCT02064582 Phase II Leuprolide Enzalutamide Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer Completed USA 0
NCT02090114 Phase II Testosterone Abiraterone Enzalutamide RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistant (The RESTORE Study) Recruiting USA 0
NCT02099864 Phase II Enzalutamide Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy Active, not recruiting USA 0
NCT02106507 Phase I Apalutamide + Everolimus ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate Active, not recruiting USA 0
NCT02111187 Phase I Sonidegib A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer Completed USA 0
NCT02123758 Phase I Abiraterone + Apalutamide + Prednisone A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer Active, not recruiting USA | CAN 2
NCT02125084 Phase I Enzalutamide + Everolimus Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer Completed USA 0
NCT02125357 Phase II Enzalutamide Abiraterone Sequencing Abiraterone and Enzalutamide in mCRPC Completed CAN 0
NCT02146833 Phase II Selinexor Study of Selinexor (KPT-330) in Metastatic Castrate Resistant Prostate Adenocarcinoma Terminated USA 0
NCT02176161 Phase II Metformin Metformin Prostate Cancer Adjuvant Trial Recruiting USA 0
NCT02182622 Phase I Docetaxel Sonidegib LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel Withdrawn USA 0
NCT02194842 Phase III Enzalutamide Enzalutamide + Radium Ra 223 dichloride Phase III Radium 223 mCRPC-PEACE III (PEACE III) Recruiting CAN 10
NCT02199197 Phase II Enzalutamide Radium Ra 223 With Enzalutamide in Men With Metastatic Castration Refractory Prostate Cancer Completed USA 0
NCT02200614 Phase III Darolutamide Efficacy and Safety Study of ODM-201 in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer Active, not recruiting USA | CAN 34
NCT02203695 Phase II Enzalutamide Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy Active, not recruiting USA 0
NCT02204072 Phase I Enzalutamide Xentuzumab BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC) Active, not recruiting USA 7
NCT02207504 Phase I Crizotinib + Enzalutamide Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer Active, not recruiting USA 0
NCT02213107 Phase II Dutasteride + Enzalutamide Enzalutamide & Dutasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer. Active, not recruiting USA 0
NCT02215096 Phase I Enzalutamide GSK2636771 Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer Completed USA 1
NCT02215161 Phase II Selinexor Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide Terminated USA 0
NCT02217566 Phase II Abiraterone Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy Completed 1
NCT02217709 Phase II Phenelzine Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer Active, not recruiting USA 0
NCT02254785 Phase II Abiraterone Enzalutamide Cabazitaxel Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer Unknown status CAN 1
NCT02256111 Phase II Enzalutamide EXTEND Exercise Trial Completed USA 0
NCT02257736 Phase III Abiraterone + Apalutamide Abiraterone An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) Active, not recruiting USA | CAN 14
NCT02262910 Phase I MOR209/ES414 Study of MOR209/ES414 in Metastatic Castration-Resistant Prostate Cancer Completed USA 1
NCT02268175 Phase II Enzalutamide Abiraterone Prednisone Leuprolide Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate Active, not recruiting USA 0
NCT02284971 Phase I Varlilumab Pilot Study of SBRT and CDX-1127 in Prostate Cancer (Prostate-04) Terminated USA 0
NCT02286921 Phase II Enzalutamide Testosterone Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance Completed USA 0
NCT02303327 Phase III Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients Recruiting CAN 0
NCT02319837 Phase III Leuprolide Enzalutamide Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) Active, not recruiting USA | CAN 15
NCT02346253 Phase Ib/II Leuprolide Triptorelin Degarelix Bicalutamide Goserelin High-Dose Brachytherapy in Treating Patients With Prostate Cancer Recruiting USA 0
NCT02349139 Phase Ib/II ASN001 Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer Terminated USA 0
NCT02353715 Phase I Abiraterone Enzalutamide Sipuleucel-T Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge), Abiraterone Acetate (Zytiga) or Enzalutamide (Xtandi) Undergoing Cardiopulmonary EXercise Testing Completed USA 0
NCT02376166 Phase I Metformin Metformin for Rising PSA Remote Trial Completed USA 0
NCT02379390 Phase II Prednisone Abiraterone Enzalutamide Cabazitaxel Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enz (PRIMCAB) Terminated USA | CAN 0
NCT02381236 Phase II Mipsagargin G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer Completed USA 0
NCT02384382 Phase II Enzalutamide A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC) Completed USA 0
NCT02396368 Phase I Tasquinimod Radium Ra 223 dichloride A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer Withdrawn USA 0
NCT02407054 Phase II Enzalutamide LY3023414 A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer Completed USA 0
NCT02411786 Phase I pTVG-AR Sargramostim A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF Completed USA 0
NCT02415621 Phase I Abiraterone Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer Active, not recruiting USA 0
NCT02441517 FDA approved Enzalutamide A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel Treatment in Patients Who Have Previously Received Enzalutamide Terminated USA 0
NCT02446405 Phase III Enzalutamide Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer Unknown status USA | CAN 4
NCT02446444 Phase III Enzalutamide Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer Active, not recruiting USA 8
NCT02463799 Phase II Radium Ra 223 dichloride Sipuleucel-T Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC Active, not recruiting USA 0
NCT02472275 Phase I Leuprolide Pexidartinib Goserelin Degarelix PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer Completed USA 0
NCT02489318 Phase III Apalutamide A Phase 3 Study of JNJ-56021927 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With Low-Volume mHSPC Active, not recruiting USA | CAN 20
NCT02491411 Phase I Enzalutamide Dexamethasone Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel Terminated USA 0
NCT02494713 Phase II Degarelix Estramustine Docetaxel Doxorubicin Ketoconazole Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer Terminated USA 0
NCT02497638 Phase II Atorvastatin + Metformin LIpitor and biGuanide to Androgen Delay Trial Withdrawn CAN 0
NCT02499835 Phase Ib/II Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer Active, not recruiting USA 0
NCT02500901 Phase I Niraparib Enzalutamide Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC) Terminated USA 0
NCT02506114 Phase II PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM Ipilimumab Ipilimumab + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer Terminated USA 0
NCT02508636 Phase II Enzalutamide + Leuprolide Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Completed USA 0
NCT02532114 Phase I Enzalutamide Niclosamide Niclosamide and Enzalutamide in Treating Patients With Androgen Receptor Splice Variant-Positive, Castration-Resistant, Metastatic Prostate Cancer Completed USA 0
NCT02543255 Phase II Cabazitaxel Abiraterone + Leuprolide + Prednisone Pegfilgrastim Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial) Active, not recruiting CAN 0
NCT02560051 Phase II Degarelix Aldoxorubicin + Docetaxel + Estramustine + Ketoconazole Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer Terminated USA 0
NCT02578797 Phase I Apalutamide A JNJ-56021927 (ARN-509) QT/QTc Study Active, not recruiting USA | CAN 3
NCT02582749 Phase II Bicalutamide + Radium Ra 223 dichloride Bicalutamide Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases Terminated USA 0
NCT02601014 Phase II Ipilimumab + Nivolumab Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 Active, not recruiting USA 0
NCT02606123 Phase Ib/II EPI-506 Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer Terminated USA | CAN 0
NCT02625857 Phase I JNJ-64041809 Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer Completed USA 0
NCT02643667 Phase Ib/II Ibrutinib A Study of Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer Recruiting USA 0
NCT02655822 Phase I Atezolizumab + CPI-444 CPI-444 Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers Recruiting USA | CAN 1
NCT02677896 Phase III Enzalutamide A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Active, not recruiting USA | CAN 22
NCT02685267 Phase II Docetaxel + Enzalutamide + Prednisone Docetaxel + Prednisone Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (Doce/Enza) Terminated USA 0
NCT02685397 Phase II Enzalutamide Triptorelin Goserelin Leuprolide Management of Castration-Resistant Prostate Cancer With Oligometastases Recruiting CAN 0
NCT02703623 Phase II Ipilimumab Abiraterone + Apalutamide + Prednisone Cabazitaxel + Carboplatin A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO) Active, not recruiting USA 0
NCT02716974 Phase I Bicalutamide + Docetaxel + Leuprolide A Study of Definitive Therapy to Treat Prostate Cancer Active, not recruiting USA 0
NCT02721979 Phase II Apalutamide ARN-509 in Treating Patients With Prostate Cancer Who Are in Active Surveillance Active, not recruiting USA 0
NCT02758132 Phase I Abiraterone + Denosumab + Enzalutamide + Prednisone Denosumab + Enzalutamide Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases Terminated USA 0
NCT02768363 Phase II AdV-tk + Valacyclovir Valacyclovir Randomized Controlled Trial of ProstAtak Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) Active, not recruiting USA 1
NCT02770391 Phase II Apalutamide + Leuprolide ARN-509 and Leuprolide in Intermediate and High-risk Prostate Cancer Completed USA 0
NCT02772588 Phase II Abiraterone + Apalutamide + Leuprolide AASUR in High Risk Prostate Cancer Active, not recruiting USA 0
NCT02787005 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Chemotherapy (MK-3475-199/KEYNOTE-199) Active, not recruiting 0
NCT02788773 Phase II Durvalumab + Tremelimumab Durvalumab Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer Active, not recruiting CAN 0
NCT02793219 Phase II Docetaxel + Sipuleucel-T Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer Withdrawn USA 0
NCT02793765 Phase II Docetaxel + Sipuleucel-T Docetaxel Followed by Provenge in Metastatic Prostate Cancer Withdrawn USA 0
NCT02799602 Phase III Darolutamide Darolutamide + Docetaxel ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (ARASENS) Active, not recruiting USA | CAN 21
NCT02799706 Phase III Flutamide Degarelix Bicalutamide Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer (PEGASUS) Recruiting 8
NCT02799745 Phase II Enzalutamide A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT) (ENACT) Completed USA | CAN 0
NCT02805894 Phase Ib/II NBTXR3 NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma Terminated USA 0
NCT02811809 Phase II Leuprolide Apalutamide + Leuprolide Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer Withdrawn USA 0
NCT02814669 Phase I Atezolizumab + Radium Ra 223 dichloride Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor Completed USA 0
NCT02849990 Phase II Abiraterone + Apalutamide + Degarelix + Indomethacin + Prednisone Androgen Receptor Antagonist ARN-509, Abiraterone Acetate, Prednisone, Degarelix, and Indomethacin in Treating Patients With Localized Prostate Cancer Before Surgery Completed USA 0
NCT02861573 Phase I Dexamethasone + Docetaxel + Pembrolizumab + Prednisone Olaparib + Pembrolizumab Enzalutamide + Pembrolizumab Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) Recruiting USA | CAN 2
NCT02893917 Phase II Cediranib + Olaparib Olaparib Olaparib With or Without Cediranib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Active, not recruiting USA 0
NCT02903160 Phase II Abiraterone + Cabazitaxel + Carboplatin + Enzalutamide + Prednisone Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC) Recruiting USA 0
NCT02903368 Phase II Abiraterone + Leuprolide + Prednisone Abiraterone + Apalutamide + Leuprolide + Prednisone Neoadjuvant And Adjuvant Abiraterone Acetate + Aptilutamide Prostate Cancer Undergoing Prostatectomy Active, not recruiting USA 0
NCT02905318 Phase II Palbociclib Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting CAN 0
NCT02906605 Phase II Apalutamide Apalutamide + JNJ-64041809 A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer Withdrawn USA 0
NCT02913196 Phase I Abiraterone + Apalutamide + Docetaxel + Prednisone Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC Active, not recruiting USA 0
NCT02923180 Phase I MGA271 Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer Active, not recruiting USA 0
NCT02949284 Phase II Apalutamide Abiraterone + Apalutamide + Prednisone Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery Recruiting USA 0
NCT02952534 Phase II Rucaparib A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2) Active, not recruiting USA | CAN 10
NCT02975934 Phase III Rucaparib Docetaxel Enzalutamide Abiraterone A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3) Recruiting USA | CAN 10
NCT02987829 Phase Ib/II TRC253 A Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients Completed USA 0
NCT02991911 Phase I Enzalutamide + MEDI3726 MEDI3726 A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer Completed USA 2
NCT02995330 Phase I Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Tacrolimus + Testosterone cypionate Cyclophosphamide + Fludarabine Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer Recruiting USA 0
NCT03007732 Phase II Pembrolizumab + SD-101 Pembrolizumab Pembrolizumab in Combination With Intratumoral SD-101 Therapy Recruiting USA 0
NCT03009981 Phase III Abiraterone + Apalutamide + Degarelix + Prednisone Apalutamide + Degarelix Degarelix A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer Recruiting USA 0
NCT03012321 Phase II Abiraterone + Olaparib + Prednisone Abiraterone + Prednisone Olaparib Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects Recruiting USA 0
NCT03016312 Phase III Atezolizumab + Enzalutamide Enzalutamide IMbassador250: A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen Active, not recruiting USA | CAN 19
NCT03024216 Phase I Atezolizumab + Sipuleucel-T Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer Active, not recruiting USA 0
NCT03030885 Phase I 131I-MIP-1095 Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Completed USA 0
NCT03042468 Phase I 177Lu-PSMA-617 Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC Active, not recruiting USA 0
NCT03043807 Phase II Bicalutamide + Docetaxel + Leuprolide A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy Active, not recruiting USA 0
NCT03047135 Phase II Olaparib Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis Recruiting USA 0
NCT03070886 Phase III Bicalutamide + Docetaxel + Flutamide + Goserelin + Leuprolide + Nilutamide Bicalutamide + Flutamide + Goserelin + Leuprolide + Nilutamide Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery Recruiting USA | CAN 1
NCT03072238 Phase III Abiraterone Abiraterone + Ipatasertib Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer Active, not recruiting USA | CAN 24
NCT03076203 Phase I Niraparib + Radium Ra 223 dichloride Radium Ra 223 Dichloride and Niraparib in Treating Patients With Hormone- Resistant Prostate Cancer Metastatic to the Bone Active, not recruiting USA 0
NCT03085095 Phase III Relugolix Leuprolide A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO) Active, not recruiting USA | CAN 20
NCT03093272 Phase II Leuprolide Prednisone Apalutamide + Docetaxel A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer Terminated USA 0
NCT03093428 Phase II Pembrolizumab + Radium Ra 223 dichloride Radium Ra 223 dichloride Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC Active, not recruiting USA 0
NCT03098836 Phase II Abiraterone + Apalutamide + Prednisone Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer Active, not recruiting USA 0
NCT03147196 Phase II Bicalutamide + Raloxifene Raloxifene Bicalutamide Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery Withdrawn 0
NCT03148795 Phase II Talazoparib A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Active, not recruiting USA 13
NCT03150056 Phase I Abiraterone + Molibresib Enzalutamide + Molibresib Prednisone Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer Active, not recruiting USA | CAN 3
NCT03177460 Phase I Daratumumab Edicotinib Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer Active, not recruiting USA 0
NCT03204812 Phase II Durvalumab + Tremelimumab Tremelimumab + Durvalumab Chemotherapy Naive CRPC Completed USA 0
NCT03248570 Phase II Pembrolizumab Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects Recruiting USA 0
NCT03262103 Phase I Poly ICLC Neoadjuvant Hiltonol (PolyICLC) for Prostate Cancer Recruiting USA 0
NCT03276572 Phase I 225Ac-J591 Phase I Trial of 225Ac-J591 in Patients With mCRPC Active, not recruiting USA 0
NCT03279250 Phase II Goserelin Triptorelin Abiraterone + Apalutamide + Prednisone Leuprolide Apalutamide Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence Active, not recruiting USA 0
NCT03298087 Phase II Abiraterone + Apalutamide + Leuprolide Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer Recruiting USA 0
NCT03300505 Phase Ib/II AZD5312 + Enzalutamide ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer Recruiting USA 0
NCT03317392 Phase Ib/II Olaparib Olaparib and Radium Ra 223 Dichloride in Treating Men With Metastatic Castration-Resistant Prostate Cancer That Has Spread to the Bone Recruiting USA 0
NCT03338790 Phase II Enzalutamide + Nivolumab Nivolumab + Rucaparib Docetaxel + Nivolumab An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer Active, not recruiting USA | CAN 9
NCT03360721 Phase II Abiraterone + Apalutamide + Prednisone Study of Apalutamide and Abiraterone Acetate in Castration-Resistant Bone Metastatic Prostate Cancer Patients Suspended USA 0
NCT03361735 Phase II Leuprolide + Radium Ra 223 dichloride Goserelin + Radium Ra 223 dichloride Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer Recruiting USA 0
NCT03365791 Phase II LAG525 Spartalizumab PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Completed USA 0
NCT03371719 Phase II Apalutamide Radiation Therapy With or Without Apalutamide in Treating Patients With Stage III-IV Prostate Cancer Active, not recruiting USA | CAN 0
NCT03385655 Phase II Savolitinib Darolutamide Adavosertib Prostate Cancer Biomarker Enrichment and Treatment Selection Recruiting CAN 0
NCT03395197 Phase III Talazoparib Talazoparib + NHT vs. NHT Monotherapy in DDR+ mCRPC (TALAPRO-2) Recruiting USA | CAN 24
NCT03406858 Phase II Pembrolizumab Pembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer Recruiting USA 0
NCT03412396 Phase II Apalutamide Single Arm Study of 6-Months Neoadjuvant ARN-509 Prior to Radical Prostatectomy Active, not recruiting USA 0
NCT03413995 Phase II Rucaparib Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH) Recruiting USA 0
NCT03414034 Phase II Abiraterone + Onvansertib + Prednisone PCM-075 in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting USA 0
NCT03419234 Phase II Abiraterone + Prednisone Abiraterone + Cabazitaxel + Prednisone Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Hormone-Sensitive Prostate Cancer Previously Treated With Docetaxel Recruiting USA 1
NCT03431350 Phase Ib/II JNJ-63723283 + Niraparib A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer Recruiting USA | CAN 5
NCT03432897 Phase II Olaparib BrUOG 337: Olaparib Prior to Radical Prostatectomy For Patients With Locally Advanced Prostate Cancer and Defects in DNA Repair Genes (337) Recruiting USA 0
NCT03436654 Phase II Abiraterone + Apalutamide + Prednisone A Study of Hormonal Therapy and Apalutamide With or Without Abiraterone Acetate and Prednisone in Newly Diagnosed Prostate Cancers Recruiting USA 0
NCT03437941 Phase Ib/II CORT125281 + Enzalutamide Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC Recruiting USA 1
NCT03442556 Phase II Carboplatin + Docetaxel + Rucaparib Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency Recruiting USA 0
NCT03456804 Phase II CEP-11981 ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer Active, not recruiting USA 0
NCT03458247 Phase II Abiraterone Study of Dose Escalation of Abiraterone Actetate in Prostate Cancer (OPTIMABI) Recruiting 1
NCT03465345 Phase I Metformin + OPC Study of Metformin Plus Oligomeric Procyanidin Complex for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Withdrawn USA 0
NCT03480646 Phase Ib/II Enzalutamide Abiraterone + CPI-1205 + Prednisone CPI-1205 + Enzalutamide ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer Active, not recruiting USA 0
NCT03503344 Phase II Apalutamide Apalutamide With or Without Stereotactic Body Radiation Therapy in Treating Participants With Castration-Resistant Prostate Cancer (PILLAR) Recruiting USA 0
NCT03511196 Phase I Abiraterone + Prednisone Leuprolide Goserelin Triptorelin Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer Recruiting USA 0
NCT03516812 Phase II Olaparib + Testosterone Enanthate Testosterone Enanthate and Olaparib in Treating Participants With Castration-Resistant Prostate Cancer Active, not recruiting USA 0
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Recruiting USA 0
NCT03532217 Phase I Ipilimumab + Nivolumab + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer Active, not recruiting USA 0
NCT03533946 Phase II Rucaparib Rucaparib in Nonmetastatic prOstAte With BRCAness (ROAR) Recruiting USA 0
NCT03541928 Phase II Bicalutamide + HSV-Tk + Leuprolide + Valacyclovir Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery Recruiting USA 0
NCT03545165 Phase Ib/II 177Lu-J591 + 177Lu-PSMA-617 177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC Terminated USA 0
NCT03551782 Phase I Apalutamide + JNJ-63723283 A Study of JNJ-63723283, a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer Active, not recruiting USA | CAN 5
NCT03554317 Phase II Nivolumab + Testosterone cypionate COMbination of Bipolar Androgen Therapy and Nivolumab Active, not recruiting USA 0
NCT03556904 Phase II Abiraterone + Docetaxel + Enzalutamide FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE) Recruiting USA 0
NCT03565835 Phase II Abiraterone + Prednisone Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer Active, not recruiting USA 0
NCT03570476 Phase II Olaparib Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer Terminated USA 0
NCT03570619 Phase II Ipilimumab + Nivolumab Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations (IMPACT) Recruiting USA 0
NCT03572387 Phase II Azacitidine + Leuprolide + Tretinoin A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment Recruiting USA 0
NCT03577028 Phase I HPN424 Study of HPN424 in Patients With Advanced Prostate Cancer Recruiting USA 1
NCT03579654 Phase II Proscavax Study of Proscavax Vaccine in Patients With Localized Prostate Cancer vs Active Surveillance Not yet recruiting USA 0
NCT03600350 Phase II Nivolumab + pTVG-HP plasmid DNA vaccine + Sargramostim pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer Recruiting USA 0
NCT03637543 Phase II Nivolumab Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer Recruiting USA 0
NCT03649841 Phase II Abiraterone + Prednisone Abiraterone + Prednisone + Radiotherapy Effects of Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Radiation on Prostate Cancer Recruiting USA 0
NCT03678025 Phase III Docetaxel Nilutamide Triptorelin Bicalutamide Leuprolide Degarelix Goserelin Flutamide Prednisone Abiraterone Histrelin acetate Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Recruiting USA 0
NCT03686683 Phase III Sipuleucel-T Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer (ProVent) Active, not recruiting USA 0
NCT03690141 Phase II Tomivosertib A Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC) Completed USA 0
NCT03693612 Phase Ib/II GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors Active, not recruiting USA | CAN 1
NCT03706365 Phase II Abemaciclib + Abiraterone + Prednisone Abiraterone + Prednisone A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Active, not recruiting USA 8
NCT03712930 Phase II Pamiparib Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency Terminated USA 3
NCT03724747 Phase I BAY 2315497 Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Metastatic Castration Resistant Prostate Cancer Recruiting USA 3
NCT03725761 Phase II Sacituzumab govitecan-hziy IMMU-132 in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy Suspended USA 0
NCT03732820 Phase III Abiraterone Abiraterone + Olaparib Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer Active, not recruiting USA | CAN 16
NCT03734653 Phase I Enzalutamide + Testosterone Testosterone Therapy in Castration Resistant Prostate Cancer Recruiting USA 0
NCT03748641 Phase III Abiraterone + Niraparib + Prednisone Abiraterone + Prednisone A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer Recruiting USA | CAN 27
NCT03753243 Phase II Enzalutamide + Pembrolizumab Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer Recruiting USA 0
NCT03767244 Phase III Apalutamide Abiraterone + Apalutamide Prednisone A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy Recruiting USA | CAN 17
NCT03770455 Phase II Avelumab + Enzalutamide Abiraterone + Avelumab Phase II Trial of Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC Active, not recruiting USA 0
NCT03787680 Phase II AZD6738 + Olaparib Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial) Recruiting USA 0
NCT03805594 Phase I 177Lu-PSMA-617 + Pembrolizumab 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting USA 0
NCT03809000 Phase II Goserelin Bicalutamide Enzalutamide Leuprolide A Trial to See What the Results Are for Radiation Therapy and Hormone Therapy vs Radiation Therapy With Enhanced Hormone Therapy With Enzalutamide for Patients With PSA Recurrence After Surgery (STEEL) Recruiting USA | CAN 0
NCT03821246 Phase II Atezolizumab + Emactuzumab Atezolizumab Atezolizumab + Enzalutamide Neoadjuvant Atezolizumab With or Without Enzalutamide in Localized Prostate Cancer Given Before Radical Prostatectomy Recruiting USA 0
NCT03821792 Phase II Abiraterone + Apalutamide + Prednisone Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer Recruiting USA 0
NCT03827473 Phase II Abiraterone + Prednisone Docetaxel Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer (ACADEMIC) Terminated USA 0
NCT03829930 Phase I Entinostat + Enzalutamide Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer Recruiting USA 0
NCT03833921 Phase II Abiraterone + Prednisone Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer (APRE) Recruiting USA 0
NCT03834493 Phase III Enzalutamide + Pembrolizumab Enzalutamide Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) Recruiting USA | CAN 20
NCT03834506 Phase III Docetaxel + Prednisone Dexamethasone + Docetaxel + Pembrolizumab + Prednisone Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921) Recruiting USA | CAN 19
NCT03834519 Phase III Abiraterone + Prednisone Enzalutamide Olaparib + Pembrolizumab Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010) Recruiting USA | CAN 18
NCT03837353 Phase Ib/II DKN-01 DKN-01 + Docetaxel A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1 Recruiting USA 0
NCT03840200 Phase Ib/II Ipatasertib + Rucaparib A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. Active, not recruiting USA 4
NCT03861403 Phase Ib/II Avelumab + Cyclophosphamide + TRX518 A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors Terminated USA 0
NCT03886493 Phase II Dupilumab Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer Terminated USA 0
NCT03888612 Phase I ARV-110 A Phase 1 Clinical Trial of ARV-110 in Patients With Metastatic Castration-resistant Prostate Cancer. (mCRPC) Recruiting USA 0
NCT03899987 Phase II Aspirin + Rintatolimod Aspirin + Interferon alpha-2b + Rintatolimod Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery Recruiting USA 0
NCT03902951 Phase II Abiraterone + Apalutamide + Leuprolide Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer Recruiting USA 0
NCT03926013 Phase I JNJ-63898081 A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors Recruiting USA | CAN 1
NCT03939689 Phase II Enzalutamide 131I-MIP-1095 + Enzalutamide Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (ARROW) Recruiting USA | CAN 0
NCT03964337 Phase II Cabozantinib Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer (SPARC) Recruiting USA 0
NCT03972657 Phase Ib/II Cemiplimab + REGN5678 Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer Recruiting USA 0
NCT03999515 Phase II Enzalutamide + Erdafitinib Abiraterone + Erdafitinib Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer Recruiting USA 0
NCT04015622 Phase II Docetaxel Enzalutamide PROTRACT (PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA) STUDY (PROTRACT) Recruiting CAN 0
NCT04019327 Phase Ib/II Talazoparib + Temozolomide A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer Recruiting USA 0
NCT04025372 Phase II Bicalutamide Darolutamide INTREPId (INTermediate Risk Erection PreservatIon Trial) Recruiting USA 0
NCT04033328 Phase I Enzalutamide + ORIC-101 Study of ORIC-101 in Combination With Enzalutamide Recruiting USA 0
NCT04033432 Phase II sEphB4-HSA sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Active, not recruiting USA 0
NCT04037254 Phase II Niraparib Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer Recruiting USA 0
NCT04060394 Phase Ib/II Afuresertib + LAE001 + Prednisone Afuresertib Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC Recruiting USA 0
NCT04070209 Phase II Darolutamide Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X) Recruiting CAN 0
NCT04077021 Phase I CCW702 First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer Recruiting USA 0
NCT04090528 Phase II Pembrolizumab + pTVG-AR + pTVG-HP plasmid DNA vaccine + Sargramostim Pembrolizumab + pTVG-HP plasmid DNA vaccine + Sargramostim pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer Recruiting USA 0
NCT04090775 Phase II Cyclophosphamide + Ipilimumab + Nivolumab A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma Recruiting USA 0
NCT04097002 Phase Ib/II ORCA-010 First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients. Recruiting CAN 0
NCT04100018 Phase III Docetaxel + Nivolumab + Prednisone Docetaxel + Prednisone A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer (CheckMate 7DX) Recruiting USA | CAN 26
NCT04104893 Phase II Pembrolizumab A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation (CHOMP) Recruiting USA 0
NCT04109729 Phase Ib/II Nivolumab + Radium Ra 223 dichloride Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer (Rad2Nivo) Recruiting USA 0
NCT04116775 Phase II Enzalutamide + Pembrolizumab Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer. Recruiting USA 0
NCT04126070 Phase II Docetaxel + Nivolumab Leuprolide Goserelin Degarelix Nivolumab + Docetaxel + ADT in Metastatic Hormone Sensitive Prostate Cancer Recruiting USA 0
NCT04134260 Phase III Abiraterone + Apalutamide + Prednisone Testing the Addition of the Drugs, Apalutamide and Abiraterone Acetate With Prednisone, to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer Recruiting USA 0
NCT04157088 Phase II Enzalutamide Darolutamide Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC) (DaroAcT) Recruiting USA 0
NCT04175431 Phase II Abiraterone + Prednisone Fluciclovine (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study Recruiting USA 0
NCT04176081 Phase II Darolutamide + Degarelix Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer (SChLAP/IDC) Not yet recruiting CAN 0
NCT04179396 Phase I Enzalutamide + Rucaparib Abiraterone + Rucaparib Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) (RAMP) Active, not recruiting USA 0
NCT04179864 Phase I Enzalutamide + Tazemetostat Abiraterone + Prednisone + Tazemetostat A Phase 1b/2 Open-Label Study in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer Recruiting USA 0
NCT04191096 Phase III Enzalutamide + Pembrolizumab Enzalutamide Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) Recruiting USA | CAN 26
NCT04194554 Phase Ib/II Abiraterone + Leuprolide + Niraparib + Prednisone A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer (ASCLEPIuS) Recruiting USA 0
NCT04207255 Phase II ABC294640 + Enzalutamide ABC294640 + Abiraterone Addition of Opaganib to Androgen Antagonists in Patients With mCRPC Recruiting USA 0
NCT04237584 Phase III Darolutamide Darolutamide + Radium Ra 223 dichloride Enzalutamide Enzalutamide + Radium Ra 223 dichloride A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients (ESCALATE) Recruiting USA 0
NCT04262154 Phase II Abiraterone + Atezolizumab + Leuprolide + Prednisone Study of Abiraterone Acetate, Atezolizumab, Lupron, and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer Recruiting USA 0
NCT04272645 Phase II Abemaciclib + Atezolizumab Abemaciclib Atezolizumab Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer Withdrawn USA 0
NCT04288687 Phase II Niraparib A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects Recruiting USA 0
NCT04291664 Phase I Abiraterone + Prednisone DST-2970 + Prednisone PK and Dose Escalation and Expansion Study of DST-2970 Recruiting USA 0
NCT04296578 Phase I Abiraterone + Prednisone + Sodium Selenite Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone Not yet recruiting USA 0
NCT04298983 Phase II Abemaciclib Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer (RAD 1805) Recruiting USA 0
NCT04301414 Phase I BMS-986218 + Degarelix Degarelix Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer (Neo-Red-P) Recruiting USA 0
NCT04331717 Phase II Leuprolide Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer (BASH-PC) Recruiting USA 0
NCT04335682 Phase II Darolutamide Enzalutamide Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide Not yet recruiting USA 0
NCT04336943 Phase II Durvalumab + Olaparib Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load Recruiting USA 0
NCT04363164 Phase II Testosterone Enanthate Testosterone cypionate Enzalutamide Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression Recruiting USA 0
NCT04382898 Phase Ib/II BNT112 + Cemiplimab BNT112 PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) (PRO-MERIT) Recruiting USA 3
NCT04397276 Phase I JNJ-70218902 A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors Recruiting USA | CAN 2
NCT04404140 Phase I Atezolizumab + Docetaxel + Ipatasertib A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC). Recruiting USA 4
NCT04423211 Phase III Apalutamide + Leuprolide Apalutamide + Goserelin Leuprolide Goserelin Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Using PET/CT Imaging Recruiting USA 0
NCT04428203 Phase I Cannabidiol Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer Active, not recruiting USA 0
NCT04428788 Phase I CC-94676 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer Recruiting USA 0
NCT04446117 Phase III Enzalutamide Atezolizumab + Cabozantinib Abiraterone + Prednisone Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02) Recruiting USA | CAN 20
NCT04471974 Phase II Enzalutamide + Pembrolizumab + ZEN-3694 ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer Recruiting USA 0
NCT04493853 Phase III Abiraterone + Capivasertib Abiraterone Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency (CAPItello-281) Recruiting USA | CAN 31
NCT04495179 Phase II AZD4635 + Durvalumab AZD4635 + Cabazitaxel + Durvalumab A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC. (AARDVARC) Recruiting USA 8
NCT04497844 Phase III Abiraterone + Niraparib + Prednisone Abiraterone + Prednisone A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE) Recruiting USA | CAN 30
NCT04506567 Phase Ib/II 225Ac-J591 Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC Recruiting USA 0
NCT04513717 Phase III Bicalutamide + Buserelin Buserelin + Flutamide Abiraterone + Apalutamide + Degarelix + Prednisone Abiraterone + Apalutamide + Buserelin + Prednisone Flutamide + Triptorelin Degarelix + Flutamide Abiraterone + Apalutamide + Leuprolide + Prednisone Flutamide + Leuprolide Flutamide + Goserelin Abiraterone + Apalutamide + Histrelin acetate + Prednisone Bicalutamide + Triptorelin Bicalutamide + Goserelin Flutamide + Histrelin acetate Bicalutamide + Degarelix Abiraterone + Apalutamide + Goserelin + Prednisone Abiraterone + Apalutamide + Prednisone + Triptorelin Bicalutamide + Leuprolide Bicalutamide + Histrelin acetate Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Recruiting USA 0
NCT04523207 Phase II Apalutamide A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases Recruiting USA 0
NCT04556617 Phase Ib/II Olaparib + PLX2853 Abiraterone + PLX2853 + Prednisone PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Recruiting USA 1
NCT04557449 Phase I Letrozole + PF-07220060 Fulvestrant + PF-07220060 PF-07220060 Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4) Recruiting USA 0
NCT04569461 Phase II Pembrolizumab Trimodality Approach to Localized Prostate Cancer: Pembrolizumab, ADT, and SBRT Followed by Prostatectomy (TALON) Not yet recruiting USA 0
NCT04576871 Phase I 225Ac-J591 Re-treatment 225Ac-J591 for mCRPC Recruiting USA 0
NCT04577833 Phase I Abiraterone + Niraparib + Prednisone A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer Recruiting USA 12
NCT04628988 Phase I Abiraterone + CC-90011 + Prednisone A Study of CC-90011 and Comparators in Participants With Prostate Cancer Not yet recruiting USA 0
NCT04631601 Phase I AMG 160 + AMG 404 AMG 160 + Enzalutamide Abiraterone + AMG 160 AMG 404 Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting USA 2
NCT04635059 Phase II Pacritinib Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer (BLAST) Not yet recruiting USA 0
NCT04647526 Phase III Abiraterone + Dexamethasone Abiraterone + Prednisone Enzalutamide PNT2002 Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH) Recruiting USA | CAN 0
NCT04655365 Phase II Enzalutamide Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer. (PROSTEP-002) Not yet recruiting CAN 0
NCT04666129 Phase I Abiraterone + Prednisone + Relugolix Study of Relugolix in Men With High-Risk Metastatic Castration-Sensitive Prostate Cancer or Metastatic Castration-Resistant Prostate Cancer Recruiting USA 0
NCT04709276 Phase II Cabazitaxel + Carboplatin + Ipilimumab + Nivolumab A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP) Not yet recruiting USA 0
NCT04726332 Phase I Abiraterone + Prednisone + XL102 Fulvestrant + XL102 XL102 Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors Recruiting USA 0
NCT04734730 Phase II Abiraterone + Bicalutamide + Leuprolide + Prednisone + Talazoparib Abiraterone + Goserelin + Prednisone + Talazoparib Abiraterone + Degarelix + Prednisone + Talazoparib Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer Not yet recruiting USA 0
NCT04736199 Phase III Darolutamide Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer (ARANOTE) Recruiting CAN 15
NCT04748042 Phase II Abiraterone + Olaparib + Prednisone Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) Not yet recruiting USA 0
NCT04751929 Phase II Abemaciclib + Atezolizumab Atezolizumab Abemaciclib Abemaciclib With or Without Atezolizumab for mCRPC Not yet recruiting USA 0
NCT04754425 Phase II Erdafitinib Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer Not yet recruiting USA 0
NCT04781374 Phase II Neratinib Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer Not yet recruiting USA 0
NCT04821622 Phase III Enzalutamide Enzalutamide + Talazoparib Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC Recruiting USA 0
NCT04824937 Phase II Talazoparib + Telaglenastat Telaglenastat + Talazoparib In Prostate Cancer Not yet recruiting USA 0
NCT04844749 Phase III Abiraterone Enzalutamide VERU-111 Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent (VERU-111) Not yet recruiting USA 0